Common FDA Mistakes That Kill Biotech Startups

Most biotech startups do not fail because the science was wrong. They fail because of avoidable errors in how they engaged the regulatory system. The same mistakes recur across companies and decades, and they are largely preventable. This essay catalogs the most common FDA-related mistakes that kill biotech startups, drawn from how the development process actually works. It is educational and is not investment advice.

Mistake one: choosing the wrong endpoint

The single most expensive error is designing a trial around an endpoint that the company likes but that regulators will not accept as proof of benefit. An endpoint is the specific outcome a trial measures, and if it is not one the regulator considers meaningful, even a statistically successful trial can fail to support approval. Companies that pick endpoints late, or assume an endpoint will be accepted without confirming it, can spend years and most of their capital generating data that does not answer the question that matters. The structure that defines acceptable endpoints is part of the founder's guide to the FDA approval process.

Mistake two: underpowered or poorly designed trials

A trial that is too small, or designed without adequate controls, may fail to detect a real effect or may produce a result regulators cannot trust. Because success rates fall sharply at each clinical phase, a company that cuts corners on trial design raises its already-high odds of failure (Hay et al., 2014). Underpowering a pivotal trial to save money is a frequent and fatal economy, because a near-miss in an underpowered study often cannot be rescued and forces the whole expensive trial to be repeated.

Mistake three: treating manufacturing as an afterthought

Many founders focus on clinical data and neglect chemistry, manufacturing, and controls until late, only to discover that they cannot produce their product consistently enough to satisfy regulators. For biologics especially, the process is part of the product, and an unvalidated or unreliable manufacturing process can halt a program at the threshold of approval. This is why manufacturing capability is a strategic asset rather than a logistics detail, a point developed in the analysis of the manufacturing moat.

Mistake four: failing to engage regulators early

Regulators offer structured opportunities to align on trial design and endpoints before a company commits to an expensive program, beginning around the investigational application that permits human testing (U.S. FDA). Startups that skip or underuse these interactions, or that treat them as adversarial rather than as guidance, often learn too late that their plan was never going to work. Early, candid engagement is one of the cheapest forms of risk reduction available, and failing to use it is a recurring unforced error.

Mistake five: misjudging timeline and cash

Drug development is long and expensive, with the capitalized cost of a single approved drug estimated at roughly 2.6 billion dollars in 2013 terms (DiMasi, Grabowski, and Hansen, 2016). Startups that underestimate how long approval takes, or that run out of money before reaching a decisive readout, fail regardless of how good the science is. The cumulative probability of moving from first-in-human testing to approval sits in the low double digits, which means a company must be financed to survive a long, uncertain journey (Wong, Siah, and Lo, 2019). Misjudging this is less a regulatory mistake than a strategic one, but it is inseparable from the regulatory timeline.

The pattern These mistakes are well documented and recur across companies. They are about strategy and execution, not bad luck.

Why these mistakes persist

If these errors are so well known, why do they keep happening? Partly because founders are often scientists who are most comfortable with the science and least experienced with regulators. Partly because the incentives to move fast and show progress can push hard decisions, like confirming an endpoint or investing in manufacturing, until later. And partly because each company believes its situation is exceptional. The antidote is experience and humility, which is why investors weigh the team's track record so heavily, a theme in what makes a company investable.

The takeaway for founders

Avoiding these mistakes is not glamorous, but it is decisive. Confirm endpoints with regulators early, design trials properly the first time, treat manufacturing as a core asset, use regulatory interactions fully, and finance the company for the real timeline. Founders who do these things do not guarantee success, but they remove the self-inflicted failures that sink so many programs. The broader pattern of how companies break is explored in why biotech startups fail, and for how this judgment is applied in practice, see the advisory practice.

The meta-mistake: optimism as a strategy

Underneath the specific errors sits a single deeper one: treating optimism as a substitute for planning. Founders, by temperament, believe their program is the exception, that their endpoint will be accepted, that their trial will read out clean, that their manufacturing will come together, and that capital will be available when they need it. This optimism is necessary to start a company, but it becomes dangerous when it replaces rigorous contingency planning. The strongest teams pair conviction with a clear-eyed view of what could go wrong and a plan for each scenario, including the unglamorous ones. They model the cash needed to survive a delayed trial, they confirm assumptions with regulators rather than hoping, and they build manufacturing before they are forced to. The discipline is not pessimism. It is preparing for the base rates that govern the sector while still believing the program can succeed. That balance, between the optimism to build and the realism to survive, is what separates teams that navigate the regulator from those it defeats, and it is central to what makes a company investable.